

- B1
- a) dry admixing paroxetine and excipients in a mixer to form a mixture; or
 - b) dry admixing paroxetine and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and
 - c) compressing the mixture into tablets using a single punch or rotary tablet machine;
- provided that one of the excipients is not microcrystalline cellulose.

REMARKS

Applicants respectfully request examination of the instant application as amended herein. The instant amendments are made to eliminate multiple dependent claims and put the application in better form for examination. Please add the enclosed Abstract as the Abstract in this application.

If any matters remain to be resolved before search, examination and allowance, or discussion of any matter will facilitate the prosecution of this application, the Examiner is invited to call the undersigned attorney at the number indicates below.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090
n:\mtf\wjd\responses\IP30835DIV2C2PreliminaryAmendment.doc

Predecessor Serial No.: 09/411,764
Predecessor Group Art Unit No.: 1615

- 3 -

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Applicants note that all of the previously pending claims have been deleted and replaced by a new claim set. As such, a marked-up version of the claims is not necessary.

2025-04-04 10:00:00